News

ImCheck Therapeutics once again recognized for its potential to become an international leader in healthcare innovation

|   Leadership & Corporate

  • ImCheck is a winner of the French Tech 120 program for the 5th year in a row and a winner of the new French Tech 2030 program announced nearly a year ago.
  • ImCheck is one of the few therapeutics-focused biotech and healthcare start-up/scale-up companies selected as one of the 120 companies for the fifth edition of the French Tech Next40/120 program and as one of the 125 recipients of the first edition of the French Tech 2030 program.
  • The awards highlight ImCheck as one of the leaders among the companies supporting the ambitions of the Innovation Santé 2030 plan.

Marseille, May 21, 2024 - ImCheck Therapeutics announced today that it is part of the prestigious French Tech 120 for the fifth year in a row.  Being once again a #FT120 winner and one of the 125 companies selected for the #FrenchTech2030 underscores ImCheck's potential to become a world-class leader in immunotherapy. ImCheck benefits from these two programs of excellence launched by the French government, serving one of the 6 priorities of France 2030: positioning France as a sovereign European leader in healthcare innovation.

"Anchored in our regional healthcare ecosystem in Marseille and backed by a syndicate of prestigious international investors, we are delighted to once again have the support and recognition of the French government and its agencies, and intend to actively contribute to France's sovereignty in healthcare innovation. We are more determined than ever to become a champion in immunotherapy on a global scale," said Pierre d'Epenoux, CEO of ImCheck Therapeutics.

We would like to thank Clara Chappaz, Lise Alter, Marina Ferrari, Bruno Le Maire, Gabriel Attal and Emmanuel Macron for their support.

  Back